33
Participants
Start Date
April 1, 2019
Primary Completion Date
February 1, 2021
Study Completion Date
February 1, 2021
Community Pharmacists Vaccinating Against Cancer
Upon completing informed consent, parents of children who have received Dose 1 of the HPV vaccine at the recent clinical visit will be invited to participate in the study. Upon completing the demographic form and pre-test survey for the study, they will be randomized to intervention or control group. Participants in the intervention group will be asked to complete the additional vaccine doses with their community pharmacist. A provider from the participating clinic will electronically prescribe the HPV vaccine dose. Participants in the control group will be scheduled to return to the clinic (based on the vaccine schedule) to complete the vaccine series. The research team will conduct a follow-up survey six months after baseline for each participant. A sample (n=30) of intervention and control group participants will be invited to participate in an in-depth interview to gauge both parents' and children's' acceptability of this intervention.
Adelante Healthcare Mesa, Mesa
Collaborators (1)
Adelante Healthcare
UNKNOWN
National Institute on Minority Health and Health Disparities (NIMHD)
NIH
Arizona State University
OTHER